Summit Therapeutics Inc.
SMMTNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $11.96B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $12.07$29.23
- Volume (live)
- -
- Avg. volume (3M)
- 6.83M
Summit Therapeutics (SMMT) Stock Price & Financial Analysis
Summit Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $14.56 - $15.41 |
|---|---|
| 52-Week High | $29.23 |
| 52-Week Low | $12.07 |
| Open | $15.39 |
| Volume (last close) | 4.32M |
| Average Volume (3M) | 6.83M |
| 50-Day MA | $15.62 |
|---|---|
| 200-Day MA | $16.32 |
| 1-Year Change | −26.77% |
| Market Cap | 11.96B |
|---|---|
| Shares Outstanding | 778.18M |
| Price to Book (P/B) | 18.99 |
| EV/EBITDA | -13.22 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Summit Therapeutics at a Glance
As of the Oct 16, 2026 close, Summit Therapeutics (SMMT) has a market capitalization of $11.96B.
As of its latest reported balance sheet, it holds $419.37M in cash and securities against $20.38M of debt, a net cash position of $398.98M.
Summit Therapeutics does not currently pay a dividend.
The share price is down 26.8% over the past year. At $14.63 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $12.07 to $29.23, below its 200-day moving average of $16.32.
Based on 17 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $26.79, 83.1% above the Oct 16, 2026 close.
Frequently Asked Questions About Summit Therapeutics
What is the current stock price for SMMT?
As of the Oct 16, 2026 close, SMMT stock trades at $14.63. The 52-week range is $12.07–$29.23, with a day range of $14.56–$15.41.
What is the P/E ratio for SMMT?
The P/E ratio (Price-to-Earnings) for SMMT is shown in the Key Statistics section. This valuation metric helps compare Summit Therapeutics Inc. to industry peers.
Does SMMT pay dividends?
Summit Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for SMMT?
Based on ratings from 17 professional analysts over the last 90 days, the consensus for SMMT is Buy. The average 12-month price target is $26.79, a 83.1% upside from the Oct 16, 2026 close of $14.63.
What is the market cap of SMMT?
As of the Oct 16, 2026 close, Summit Therapeutics's market capitalization is $11.38B, classifying it as a large-cap company. Summit Therapeutics operates in the Healthcare sector within the Biotechnology industry.